Last reviewed 2026-05-14 · How we verify

JNJ-64232025 IV

Janssen Research & Development, LLC · Phase 1 active Small molecule

JNJ-64232025 IV is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 1 development.

At a glance

Generic name	JNJ-64232025 IV
Sponsor	Janssen Research & Development, LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JNJ-64232025 IV CI brief — competitive landscape report
JNJ-64232025 IV updates RSS · CI watch RSS
Janssen Research & Development, LLC portfolio CI

Frequently asked questions about JNJ-64232025 IV

What is JNJ-64232025 IV?

JNJ-64232025 IV is a Small molecule drug developed by Janssen Research & Development, LLC.

Who makes JNJ-64232025 IV?

JNJ-64232025 IV is developed by Janssen Research & Development, LLC (see full Janssen Research & Development, LLC pipeline at /company/johnson-johnson).

What development phase is JNJ-64232025 IV in?

JNJ-64232025 IV is in Phase 1.

Manufacturer: Janssen Research & Development, LLC — full pipeline
Compare: JNJ-64232025 IV vs similar drugs
Pricing: JNJ-64232025 IV cost, discount & access